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Chemerin is a novel adipokine, suggested to be involved in insulin resistance in obesity and
type 2 diabetes and may be an attractive candidate for assessing risk of atherosclerotic car-
diovascular disease. The aim is to examine the relationship of chemerin and markers of
inflammation, and predictors of atherosclerosis in the metabolic syndrome, and type 2 dia-
betes mellitus in Saudi Arabians. Twenty healthy control subjects (group I), 20 patients with
type 2 diabetes mellitus (group II), in addition to 20 subjects with metabolic syndrome (group
III) are examined by anthropometric and blood pressure measurement, laboratory in-
vestigations including fasting and post-prandial blood sugar, fasting serum insulin, lipid
profile and serum chemerin and leptin levels. Moreover, tumor necrosis factor e a (TNF e a),
high sensitivity C-reactive protein (hsCRP) levels, and interleukin 6 (IL6) are measured.
Vascular healthwas assessed by the brachiale ankle pulsewave velocity (baPWV) and carotid
intima-media thickness (IMT). Homeostasis Model Assessment-Insulin Resistance Index
(HOMA-IR) and the cardio-vascular risk value were calculated. Our present study revealed a
significant a positive correlation between serum chemerin level and fasting and post-prandial
blood sugar, IL6 andTNF-a (p< 0.05, respectively) in group II and III.Moreover, IMTandbaPWV
are positively associated with chemerin in both groups (p < 0.01, respectively) but not with
leptin. In group III, it was revealed that, chemerin, systolic blood pressure and waist circum-
ference are risk factors determining baPWV values and the three variables together account, Laboratory Department, College of Applied Medical Sciences, Taif University, Taif, Saudi
M. Ali).
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markers of inflammation and predictors of atherosclerosis in the metabolic syndrome, and
type2diabetes and it is an independent factordeterminingarterial stiffness in SaudiArabians.
Copyright 2013, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction (Cohn, 1999; van Popele et al., 2001) but also a prognostic pre-Adipose tissue is now considered as an active endocrine organ
that secrets a large number of bioactive mediators (adipo-
kines) that signal to brain, liver, skeletal muscle, and the im-
mune system, the important metabolic organs in the body
(Yan et al., 2012). These adipokines include adiponectin, lep-
tin, omentin, resistin, retinol binding protein-4(RBP-4), tumor
necrosis factor-a (TNF-a), interleukin-6 (IL6), vaspin, visfatin
and chemerin (Yan et al., 2012). Dysregulation of pro inflam-
matory and anti inflammatory adipokines secretion in obesity
may serve as a pathogenic link between obesity, insulin
resistance and cardiovascular diseases (Roh et al., 2007;
Goralski, 2007). Chemerin, also known as tazarotene induced
gene 2 (TIG2) and retinoic acid receptor responder 2
(RARRES2), is a recently discovered adipokine that has been
reported to act by its binding to the chemerin receptor
(Chemerin R, chemokine like receptor 1, G protein-coupled
receptor) (Roh et al., 2007). It is secreted as an 18 kDa inac-
tive pro-protein and undergoes extracellular serine protease
cleavage of the C-terminal portion of the protein to generate
the 16 kDa active chemerin which is present in plasma and
serum (Goralski et al., 2007). The functions of chemerin vary
dependent on the ways how it is cleaved. For example,
chemerin 21e157 has a strong chemotactic effect and is
responsible for an early inflammatory reaction of the immune
cells, whereas chemerin 21e154 is anti-inflammatory via
inhibiting macrophage activation (Du et al., 2009). Chemerin
and its receptor/ChemR23 are expressed abundantly in adi-
pose tissue, suggesting its function in autocrine/ paracrine
fashion (Ernst et al., 2012). Type 2 diabetes mellitus is a group
of disorders characterized by hyperglycemia and associated
with microvascular and macrovascular complications. Hy-
perglycemia results from lack of endogenous insulin or
resistance to the action of insulin in muscle, fat and liver in
addition to an inadequate response by the pancreatic beta
cells (Wolfs et al., 2009).
It was originally reported to be present in circulation in
plasma and serum, respectively, at 3.0 and 4.4 nM concen-
trations in humans, and 0.6 and 0.5 nM concentrations inmice
(Goralski et al., 2007). Serum chemerin concentrations are
elevated in obese, insulin-resistant, and inflammatory states
in vivo and suggested to be an obvious cause of insulin
resistance (Hart and Greaves, 2010).
It may link obesity and inflammation since chemerin is
a pro-inflammatory cytokine that recruits and activates im-
mune cells and contributes to inflammation by promoting
macrophage adhesion to vascular cell adhesion molecule-1
(VCAM-1) and fibronectin, (Ouchi et al., 2011). Pulse wave ve-
locity (PWV) is a marker of arterial stiffness (Asmar et al., 1995;
Lehmann, 1999 and Yufu et al., 2004) and a reliable indicator of
vascular damage. It is not only a marker of vascular damagedictor (Cruickshank et al., 2002; Laurent et al., 2003; Pannier
et al., 2005).
Obesity and atherosclerosis are increasingly viewed as in-
flammatory states. Biomarkers that integrate metabolic and
inflammatory signals may be attractive candidates for
assessing risk of atherosclerotic cardiovascular disease (Rajala
et al., 2003).
The accumulation of chemerin in an atherosclerotic lesion
could attract immune cells which add to the remodeling of the
vessel wall, the alteration of insulin sensitivity and glucose
uptake in adipocytes and skeletal muscle and the direct in-
flammatory effect on vascular endothelial cells all could
contribute to development of atherosclerosis (Yamawaki, 2011).
A cluster of coronary heart disease (CHD) risk factors
including high blood pressure, dyslipidemia, hyperglycemia
and central obesity is known as the metabolic syndrome that
is associated with decreased ability of insulin to stimulate
glucose disposal on peripheral target tissues (Olufadi and
Byrne, 2008).
Obesity, particularly central obesity, is the prominent risk
factor for insulin resistance and results in type 2 diabetes and
metabolic syndrome (Zeyda and Stulnig, 2009). In addition to
its immunomodulatory effects, chemerin was reported to be
associated with components of the metabolic syndrome and
the parameters of type II diabetes (Bozaoglu et al., 2007)
including body mass index (BMI), plasma triglyceride (TG)
levels, and blood pressure. Chemerin was shown to modulate
the expression of adipocyte genes involved in glucose and
lipid homeostasis such as glucose transporter-4, fatty acid
synthase, adiponectin, and leptin (Goralski, 2007) and to
enhance insulin signaling in 3T3-L1 adipocytes (Takahashi
et al., 2008). Recently, it was reported that CMKLR1 is
expressed in vascular endothelial cells and its expression is
up-regulated by tumor necrosis factor (TNF)-a, interleukin
(IL)-1b, or IL-6 (Kaur et al., 2010). However, mechanisms of
actions of chemerin on vascular endothelial cells remain to be
fully clarified. The known junction of adipocyte and macro-
phage function of chemerin may provide an interesting link
between obesity, inflammation, and atherosclerosis and dia-
betes mellitus type 2 in humans (Lehrke et al., 2009).
As chemerin has a regulatory role in adipogenesis and
adipocyte metabolism, and influencing chemerin and chem-
erin R signalingmight to lead to novel therapeutic approaches
in the treatment of obesity, diabetes mellitus type 2, and
cardiovascular diseases (Goralski et al., 2007).
The aim of the present study is to examine the rela-
tionship of chemerin, markers of inflammation and pre-
dictors of atherosclerosis in the metabolic syndrome and
type 2 diabetes, and to investigate its correlation with clin-
ical and laboratory parameters of these conditions in Saudi
Arabians.
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2.1. Subjects
2.1.1. Control group I (n ¼ 20)
This group included 15 healthy male subjects and 5 females.
They were whose ages ranged from 45.00 to 68.00 year
(52.15  5.87).
2.1.2. Patients’ group (n ¼ 40)
This group included forty patients attending to Internal
Medicine Clinics for medical investigations in different hos-
pitals in Taif KSA. They were 22 males and 18 females. They
were further divided into two groups.
2.1.2.1. Group II; patients with type 2 diabetes mellitus
(n ¼ 20). This group included twenty patients, 12 males and 8
females, whose ages ranged from 41 to 56 years (Mean
49.25  3.99). Diagnosis of diabetes was according to the
Report of the Expert Committee on the Diagnosis and Classi-
fication of Diabetes Mellitus in 1997 and the follow-up reports
in 2003. We identified Type 2 diabetes mellitus by one of the
following criteria: i) Symptoms of diabetes mellitus plus
random blood sugar concentration 200 mg/dL. ii) Fasting
blood sugar (FBS) 126 mg/dL on more than one occasion. iii)
2 h post prandial plasma glucose concentration 200 mg/dL
during oral glucose tolerance test.
2.1.2.2. Group III: patients with metabolic syndrome (n ¼ 20).
This group included twenty non-diabetic patients. They were
10 males and 10 females whose ages ranged from 45.00 to
61.00 years (Mean 51.20  4.40). The metabolic syndrome was
identified by the criteria of the National Cholesterol Education
Program Adult Treatment Panel III (2002) (NCEP ATP III)
guidelines, as described by (Lin et al., 2009).
Hypertension was defined as a systolic blood pressure of
130 mmHg and/or diastolic blood pressure of 85 mmHg on
repeated measurements, or the patient receiving antihyper-
tensive treatment. (ii) Abdominal obesity was defined as waist
circumference exceeding 102 cm and 88 cm in men and
women, respectively. (iii) Fasting serum triglyceridesmore than
150 mg/dL (1.7 mmol/L) or patient receiving treatment for this
lipid abnormality. (iv) Fasting serum HDL-C less than 40 mg/dL
(1.0 mmol/L) and 50 mg/dL (1.3 mmol/L) in men and women,
respectively or patient receiving treatment for this lipid ab-
normality. (v) Fasting blood sugar 110 mg/dL (6.1 mmol/L)
Metabolic syndrome was diagnosed by the presence of three or
more of the previous criteria (Grundy et al., 2004).2.2. Exclusion criteria
A number of clinical conditions, were excluded e.g. chronic
liver disease, hepatitis B or hepatitis C virus infection, liver cell
failure as they were known to be associated with increased
serum chemerin levels (Marra and Bertolani, 2009), chronic
kidney disease and renal failure (Hu and Feng, 2011).
All individuals included in this study were subjected to:
Full history taking: focusing on family history of type 2 dia-
betes mellitus, hypertension, smoking and physical activity.All participants gave informed consent and the study followed
the rules of the Medical National Committee for Medical and
Bio-ethics. Thorough clinical examination including
waist circumference and blood pressure measurement.
Mean arterial blood pressure (MAP) was also calculated.
MAP ¼ [(2  diastolic) þ systolic]/3. Laboratory investigations
that included: fasting blood sugar, post-prandial blood sugar,
fasting insulin, lipid profile and serum chemerin and leptin
levels. The Homeostasis Model Assessment-Insulin Resis-
tance Index (HOMA-IR) and the cardio-vascular risk value
were calculated.
2.3. Sampling
Five ml of venous blood were collected after 12e14 h fasting
under complete aseptic precautions in plain test tubes
without anticoagulant. After coagulation, samples were
centrifuged (at 1500  g for 15 min). The separated serumwas
divided into three aliquots. One was designated for the im-
mediate assay of fasting glucose and lipid profile. The other
two aliquots were stored at 20 C for subsequent assay of
insulin and chemerin. Hemolysed samples were discarded.
Repeated freezing and thawing was avoided.
2.4. Methods
2.4.1. Analytical methods
2.4.1.1. Serum glucose level. It was assayed using Synchron
CX-9 (Instruments Inc.; Scienfitic Instruments Division, Fill-
erton, CA 92634, 3100, USA.) system autoanalyzer applying
enzymatic colorimetric method (Carroll et al.,1970).
2.4.1.2. Total cholesterol (TC). The analysis was done using
the Synchron CX-9 system auto-analyzer applying enzymatic
colorimetric method (Dietschy et al., 1976).
2.4.1.3. Triglycerides (TG). The analysis of TG was assayed
using the Synchron CX-9 system auto-analyzer applying
enzymatic colorimetric method (McGowan et al., 1983).
2.4.1.4. High density lipoprotein cholesterol (HDL-C). It was
assayed on the Synchron CX-9 system auto-analyzer after pre-
cipitationof LDLandVLDLbydextransulfateandmagnesiumin
the separating reagent. The LDL and VLDL portions were then
removed by centrifugation. The cholesterol in the HDL fraction
which remains in the supernatant was assayed with an enzy-
matic timed endpoint method (Assman et al., 1983).
2.4.1.5. Low density lipoprotein cholesterol (LDL-C). It was
calculated according to “Friedewald equation”:
LDL C ¼ Total cholesterol ðHDL Cþ TG=5Þ
This equation was applied provided that serum TG level is
<400 mg/dL (Friedwald et al., 1972 and Warnick et al., 1990).
2.4.1.6. CAD-risk percentage. Cardiovascular risk was calcu-
lated as HDL-C/TC% (Carl et al., 2006).
2.4.1.7. Insulin. Insulin was assayed by Micro-particle
Enzyme Immunoassay (MEIA) on the AxSYM (Abbott
Table 1 e Descriptive statistics of the studied parameters in the different studied groups.
Parameters Control group Diabetic group Metabolic syndrome P1 P2 P3
Age (yr) 52.15  5.87
(45.00e68.00)
51.20  4.40
(45.00e61.00)
49.25  3.99
(41.00e56.00)
NS .NS NS
Weight (kg) 66.25  2.22
(61.00e70.00)
70.90  5.20a
(66.00e84.00)
78.00  4.17bc
(71.00e86.00)
<.05 <.001 <.001
Height (cm) 161.55  3.24
(156.00e168.00)
158.90  2.36a
(155.00e163.00)
161.85  3.22c
(157.00e168.00)
<.05 NS .003
BMI (kg/m2) 25.41  1.22
23.68e28.05
27.31  2.27a
24.26e32.40
29.53  2.04bc
25.00e34.00
<.05 <.001 <.001
WC (cm) 81.25  6.21
68.00e91.00
101.35  6.74a
89.00e115.00
118.1  3.99bc
112.00e125.00
<.001 <.001 <.001
SBP (mmHg) 120.80  5.82
110.00e128.00
123.45  2.82a
120.00e128.00
137.40  2.93bc
134.00e145.00
<.05 <.001 <.001
DBP (mmHg) 72.00  4.78
61.00e81.00
78.20  3.19a
72.00e82.00
90.20  2.42bc
87.00e96.00
<.001 <.001 <.001
FBS (mg/dL) 76.30  4.22
67.00e81.00
156.30  9.24a
146.00e185.00
117.00  4.69bc
112.00e129.00
<.001 <.001 <.001
PPBS (mg/dL) 112.80  6.78
99.00e124.00
176.85  11.17a
157.00e199.00
126.40  3.95bc
119.00e137.00
<.001 <.001 <.001
FSI (mU/mL) 4.70  0.74
3.7e6.00
12.65  1.27a
11.00e15.00
11.60  1.31c
10.00e14.00
<.001 <.001 <.05
HOMA-IR 2.23  .43
1.13e2.89
3.69  1.26a
1.68e5.60
3.74  .68b
2.00e4.48
<.001 <.001 NS
CHOL (mg/dL) 181.65  11.20
160.00e200.00
195.05  8.08a
180.00e213.00
229.55  15.14bc
210.00e252.00
.001 <.001 <.001
LDL (mg/dL) 106.82  12.17
88.80e127.40
125.04  9.35a
109.60e152.80
161.85  15.52bc
140.00e185.40
<.001 <.001 <.001
HDL (mg/dL) 52.75  3.88
46.00e61.00
45.90  5.36a
36.00e54.00
30.50  2.06bc
27.00e34.00
<.001 <.001 <.001
TG (mg/dL) 110.30  5.16
102.00e119.00
120.50  6.64a
106.00e132.00
186.00  4.83bc
176.00e196.00
<.001 <.001 <.001
CAD-RISK (%) 7.46  2.98
3.60e15.80
15.13  4.76a
9.20e25.80
13.25  1.21b
11.51e16.11
<.001 <.001 NS
CRP (ng/ml) .06  .02
.03e.09
.24  .06a
.14e.34
.22  .05b
.15e.34
<.001 <.001 NS
IL6 ng/ml 1.26  .25
.80e1.70
2.35  .46a
1.50e2.90
2.03  .42bc
1.40e2.80
<.001 <.001 <.05
TNFa (pg/L) 2.77  .41
1.90e3.40
5.14  1.0a
3.40e6.70
4.51  1.06bc
2.30e5.90
<.001 <.001 <.05
Carotid-IMT (mm) .66  .042
.59e.75
.69  .03a
.65e.75
.63  .03bc
.58e.70
<.05 <.05 <.001
Chemerin (ng/dL) 60.15  9.57
45.00e78.00
136.70  6.45a
126.00e146.00
402.55  58.37bc
236.00e490.00
<.001 <.001 <.001
Leptin (ng/ml) 4.03  .72
2.90e5.50
6.97  1.07a
5.10e8.90
20.25  4.15bc
13.40e25.00
<.001 <.001 <.001
PWV (m/sec) 12.98  1.23
11.2e13.6
14.53  2.52a
13.5e16.5
15.05  2.34b
11.5e19.2
<.001 <.001 NS
P1 a ¼ Diabetic group compared to control group.
P2 b ¼ Metabolic syndrome compared to control group.
P2 c ¼ Metabolic syndrome compared to diabetic group.
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ford, Ireland þ353-43-31000) for the quantitative determina-
tion of insulin in human serum or plasma.
2.4.1.8. The homeostasis model assessment-insulin resistance
index (HOMA-IR). It was calculated using the equation:
HOMA IR ¼ fasting glucoseðmg=dLÞ
 fasting insulinðmU=mLÞO405
The cutoff point to define insulin resistance corresponds to
HOMA-IR 3.8 (Shirai, 2004).2.4.1.9. Chemerin. Chemerin levels were measured using a
commercially available enzyme-linked immunosorbent assay
(ELISA) kit supplied by AVISCERA BIOSCIENCE 2348 Walsh
Ave. Suite C Santa Clara, CA 95051 USA.2.4.1.10. Leptin. Plasma leptin concentration was measured by
commercially available DSL Active TM Human Leptin Enzyme-
Linked Immunosorbent ELISA kit (Diagnostic Systems Labora-
tories, USA (Hanigaya et al., 1997)). The interassay CV for this
method was <7%.
Table 2 e Correlation analysis between serum chemerin
level and other studied parameters in diabetic and
metabolic syndrome groups.
Parameter Serum chemerin
level in DM
Serum chemerin
level in MS
BMI R2 .329 .439
WC R2 .658a .706a
SBP R2 .511a .440a
DBP R2 .504a .461a
FBS R2 .536a .454a
PPBS R2 .496a .423a
FSI R2 .314 .140
HOMA-IR R2 .532a .636b
CHOL R2 .468a .751b
LDL R2 .114 .152
HDL R2 .202 .577a
TG R2 .154 .308
CAD-risk R2 .177 .475a
CRP R2 .386a .539a
IL6 R2 .746b .550a
TNF R2 .804b .527a
IMT R2 .821b .678b
Leptin R2 .008 .025
PWV R2 .486a .808b
a Correlation is significant at the 0.05 level (2-tailed).
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baPWV was measured using a volume plethysmographic
apparatus (model BP-203RPE, Colin, Co.Ltd. Komaki, Japan).
Details of this method, including the validity and reproduc-
ibility, have been described previously by Yamashina et al.
The intra- and inter-observer reproducibility of this method
was 10.0% and 8.4%, respectively. In the current study, the
baPWV was calculated as the mean of the left and right
baPWV values. Briefly, after 15 min of rest, the subjects were
examinedwhile resting in the supine position.Waveformdata
were obtained from a volume plethysmographic sensor in
cuffs on both brachiums and both ankles, and time intervals
(T) between the wave front of the brachiums and that of the
ankles were calculated. The distance (L) between the heart
and sampling points was calculated automatically according
to the subject’s height. baPWV was calculated using the
following formula: baPWV ¼ L/T (L ¼ LaLb, where La is the
path length from the heart to ankle, and Lb is the path length
from the heart to brachium). In the present study, the mea-
surement of baPWV was performed on a different occasion
from the blood collection so that the participant would be
mentally relaxed.
b Correlation is significant at the 0.01 level (2-tailed).4. Measurement of carotid IMT
The IMT of the common carotid artery was determined
using high-resolution B-mode ultrasonography (EnVisor;
Philips Medical Systems, Andover, MA, USA) with a
5e12 MHz transducer. Carotid IMT was measured using IMT
measurement software (Intima scope; Media Cross Co.,
Tokyo, Japan) at 3 levels of the lateral and medial walls of
the carotid artery, 1e3 cm proximal to the carotid bifurca-
tion. The IMT was the average value of 99 computer-based
points in the region. In the present study, the carotid IMT
was calculated as the mean of the left and right IMT value.
All measurements were recorded by one trained technician
who was blinded to the subject’s anthropometric and lab-
oratory data.5. Statistical analysis
Data are expressed as the mean  SD. Each variable was
assessed for a normal distribution using the Kolmogor-
oveSmirnov test. Statistical differences between the groups
were identified using one-way analysis of variance (ANOVA)
followed by post-test. Pearson’s correlation test was per-
formed to determine the relationships between serum
chemerin levels and study variables, including the baPWV and
mean carotid IMT values. Multiple linear step-wise regression
analysis with baPWV as a dependent variable was performed
to identify the risk factors which determined the baPWV. All
statistical results were based on two-sided tests. Data were
analyzed using Package for Social Sciences (SPSS) software for
Windows (version 12.0; SPSS Inc., Chicago, IL, USA). P < 0.05
was regarded as significant.6. Results
The results obtained in the present study in Table 1, showed
that weight, BMI, WC, Systolic blood pressure, diastolic blood
pressure, FBS, PPBS, Cholesterol, TG, LDL, IL6, TNF-a, carotid
IMT, serum chemerin levels and serum leptin were signifi-
cantly higher inmetabolic syndrome groupwhen compared to
type 2 diabetes mellitus and control groups (p < 0.001, p < 0.05
respectively). All the above parameters are significantly higher
(p< 0.001) in type 2 diabetesmellitus groupwhen compared to
control group. Moreover, height was significantly higher in
metabolic syndrome group when compared to type 2 diabetes
mellitus group (p < 0.001) but not significantly different from
control group (p > 0.05).
Fasting serum insulinwas significantly higher (p< 0.001) in
type 2 diabetes mellitus group andmetabolic syndrome group
than in the control group but it was significantly higher
(p < 0.05) in type 2 diabetes mellitus group than in metabolic
syndrome group.HOMA-IRwas significantly higher (p< 0.001)
in type 2 diabetes mellitus group and metabolic syndrome
group than in the control group but it was not significantly
different in type 2 diabetes mellitus group compared to
metabolic syndrome group (p > 0.05). HDL was significantly
lower (p< 0.001) inmetabolic syndrome group than in diabetic
and control groups, also it was significantly lower in type 2
diabetes mellitus group than in control group.
CAD-risk percentage, hs-CRP and baPWV were signifi-
cantly higher (p < 0.001) in metabolic syndrome group and in
type 2 diabetes mellitus group when compared to control
group. However, they were not significantly different in type 2
diabetes mellitus group compared to metabolic syndrome
group (Table 1). The correlation study between serum
Fig. 1 e Correlation between circulating chemerin levels and mean carotid IMT (A), and baPWV (B).
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revealed a significant a positive correlation (p < 0.05) between
serum chemerin level and both FBS and PPBS in type 2 DM and
MS group. Moreover, a significant positive correlation was
found between serum chemerin levels and each of IL6 and
TNF-a. Moreover, it is positively associated with carotid IMT
and baPWV in both groups in (Fig. 1) compared to leptin which
showed no significant correlation (p < 0.01, respectively) with
IMT and baPWV. Our correlation study also revealed a signif-
icant negative correlation between serum chemerin level
and HDL-C and a significant positive correlation (p < 0.05)
with CAD-risk in metabolic syndrome group. Moreover, a
significant positive correlation (p < 0.05) was found between
serum chemerin levels and each of systolic blood pressure,
diastolic blood pressure, waist circumference, HOMA-IR and
total cholesterol in both groups. However, a non-significant
correlation (p > 0.05) was observed between serum chemerin
and the rest of other parameters in both groups, (Table 2).
Stepwise multiple regression analysis in metabolic syndrome
group revealed that chemerin, SBP and WC are risk factors in
determining baPWV values. Chemerin alone in model 1,
chemerin together with SBP inmodel 2 and chemerin, SBP and
WC in model 3 account for 46.0% (F ¼ 15.308, p ¼ 0.001) and
69.7% (F¼ 19.586, p¼<0.001) and 76.9% (F¼ 17.713, p¼<0.001)
of the variance in baPWV values respectively (Table 3).7. Discussion
Metabolic syndrome (MetS) is a collection of physical and
laboratory abnormalities, including hypertension, hypergly-
cemia, hyperlipidemia and abdominal obesity. MetS is now
considered as a significant risk factor for cardiovascular dis-
ease and mortality in the general population (Isomaa et al.,
2001). Early prediction of the risk for CAD in patients with
MetS is important for prevention strategies. Serum bio-
markers are important tools for prediction, diagnosis, risk
stratification and therapeutic decision-making for patientswith cardiovascular disease (Corson, 2009). The results ob-
tained in the present study showed that weight, BMI, WC,
Systolic blood pressure, diastolic blood pressure, FBS, PPBS,
Cholesterol, TG, IL6, TNF-a, carotid IMT, chemerin, leptin and
baPWV were significantly higher in metabolic syndrome
group when compared to type 2 diabetes mellitus and control
groups (p < 0.001 and p < 0.05 respectively). Moreover, height
was significantly higher (p < 0.001) in metabolic syndrome
group when compared to type 2 diabetes mellitus group but
not significantly (p > 0.05) different from control group (Table
1). Our results are consistent with the study of Osman et al.
(2012), who revealed that the systolic blood pressure, dia-
stolic blood pressure, waist circumference, fasting serum in-
sulin, fasting serum glucose, HOMA-IR, total cholesterol, LDL-
C, triglycerides and serum chemerin levels were significantly
higher in metabolic syndrome group when compared to con-
trol group. However, Bozaoglu et al. (2007) described that
circulating chemerin levels in type 2 diabetes human subjects
were not significantly higher than those in normal control
subjects, this may be due to taking anti-diabetic drugs by a
proportion of their type 2 diabetic study subjects. In addition,
Blu¨her et al. (2012) proved that insulin, triglycerides and
chemerin are biomarkers that tightly correspond to changes
in body weight. Moreover, Ernst et al. (2012) stated that
CMKLR1(/) mice had lower food consumption, total body
mass, and percent body fat comparedwith wild-type controls.
These findings suggested that chemerinmay play a role in the
pathophysiology of obesity and metabolic syndrome Fig. 2.
HDL in the present study was significantly (p< 0.001) lower
in metabolic syndrome group than in diabetic and control
groups also it was significantly lower in 2 diabetes mellitus
group than in control group. These results were in agreement
with the results of Osman et al. (2012) who revealed that HDL-
C was significantly lower in metabolic syndrome group
compared to control group.
In the present study, CAD-risk percentagewas significantly
higher (p < 0.001) in metabolic syndrome group and in type 2
diabetes mellitus group when compared to control group.
Table 3 e Coefficients of the predictors of baPWV values in metabolic syndrome group.
Model Unstandardized coefficients Standardized coefficients t Sig.
B Std. Error Beta
1 (Constant) .479 .039 1.225E1 <.001
Chemerin <.001 <.001 .678 3.912 .001
2 (Constant) .255 .203 1.254E0 NS
Chemerin <.001 <.001 .609 4.519 <.001
SBP .005 .001 .492 3.655 .002
3 (Constant) .253 .183 1.381E0 NS
Chemerin <.001 <.001 .633 5.190 <.001
SBP .004 .001 .401 3.123 .007
WC .004 .002 .282 2.219 .041
aDependent Variable: IMT.
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cantly different in type 2 diabetes mellitus group compared to
metabolic syndrome group (Table 1). These results were in
disagreement with the results obtained by the study of Osman
et al. (2012) who found that CAD-risk percentage was signifi-
cantly lower in metabolic syndrome group when compared to
type 2 diabetes mellitus and control group in addition, they
revealed that CAD-risk percentage was also significantly
lower in type 2 diabetes mellitus group compared to control
group.
Our correlation study also revealed a significant negative
correlation between serum chemerin level and HDL-C and a
significantly positive correlation (p < 0.05) with CAD-risk in
metabolic syndrome group. Our results were in consistent
with the results of Osman et al. (2012) who revealed a signif-
icant negative correlation between serum chemerin levels and
HDL-C but we disagree with the results of the same study
regarding CAD-risk in metabolic syndrome patients. Also, our
results agreed with Wang et al. (2009), Dong et al. (2011), Yoo
et al. (2012) and Yan et al. (2012) who revealed that serum
chemerin levels were significantly elevated in metabolic
syndrome patients with CAD compared to those without CADFig. 2 e Correlation between circulating leptin levand healthy subjects and were associated with several car-
diovascular risk factors. Also, it was negatively correlatedwith
HDL-C levels. Moreover, a significant positive correlation was
found between serum chemerin levels and each of systolic
blood pressure, diastolic blood pressure, waist circumference,
HOMA-IR, FBS and PPBS in both groups (p< 0.05, respectively).
Our results concerning blood pressurewere in agreementwith
studies done by Stejskal et al. (2008) and Bozaoglu et al. (2009).
They revealed that chemerin serum levels correlated posi-
tively with systolic and diastolic blood pressure. Chemerin
may also be a novel regulator of blood pressure because of
good correlations with both systolic and diastolic pressure.
This hypothesis is supported by the fact that chemerin is
highly expressed in the kidney, a key site of blood pressure
regulation. Chemerin is structurally related to other circu-
lating factors, as kininogens, whose proteolytic product is the
vasoactive peptide bradykinin. Sell et al. (2009) findings can
explain our findings regarding the highly significant increase
in FBS, PPBS and HOMA-IR and their correlation to chemerin
levels in metabolic syndrome group and type 2 diabetes mel-
litus by the fact that higher chemerin release is associated
with insulin resistance by decreasing the rate of auto-els and mean carotid IMT (A), and baPWV (B).
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signaling cascades of insulin receptor-tyrosine kinase in pe-
ripheral tissues. Chemerin also inhibits glycogen synthase
kinase phosphorylation, an enzyme necessary for glycogen
synthesis and storage, and thus inhibits glucose uptake. In
addition, chemerin activates extracellular signal-regulated
kinase (ERK). Inhibition of ERK prevents chemerin-induced
insulin resistance, pointing to participation of this pathway
in chemerin action. Moreover, Takahashi et al. (2011) showed
that chemerin-deficient mice are glucose intolerant and
glucose intolerance was mainly due to increased hepatic
glucose production and impaired insulin secretion. They
suggested that chemerin and its receptor were expressed in b-
cell and chemerin regulates b-cell function and plays an
important role in glucose homeostasis in a tissue dependent
manner. In adipocytes, chemerin stimulates the differentia-
tion and insulin sensitivity (Takahashi et al., 2008), whereas it
induces the insulin resistance in skeletal muscle, suggesting
that the effects of chemerin are different dependent on the
tissue types (Sell et al., 2009). A possible relation of chemerin
to inflammatory proteins and insulin resistance in obesity and
type 2 diabetes is suggested as muscle insulin resistance is a
major risk factor for the pathogenesis of type 2 diabetes
(Lambernd et al., 2012). Chemerin downregulation during
adipocyte maturation results subsequently in lower expres-
sion of perilipin, GLUT4 (insulin-regulated glucose trans-
porter), adiponectin and leptin bymature adipocytes (Goralski
et al., 2007). Our results are also supported by a study done by
Ernst et al. (2012) who revealed that recombinant chemerin
administration exacerbated glucose intolerance in obese and
diabetic mice. This study provided evidence that serum
chemerin levels are elevated in obesity and diabetes and that
chemerin exacerbates glucose intolerance in these models by
decreasing serum insulin levels and glucose uptake in liver
tissue .Our results agree with results of El-Mesallamy et al.
(2011) and Hu and Feng (2011) who proved that serum chem-
erin levels were significantly increased in patients with type 2
diabetes and in patients with type 2 diabetes with ischemic
heart disease compared with healthy control subjects. Our
study revealed a significant positive correlation between
serum chemerin levels and each of systolic blood pressure,
diastolic blood pressure, waist circumference, HOMA-IR, FBS,
PPBS and total cholesterol in both type 2 DM and MS group
groups (p < 0.05, respectively). Our study agrees in some
findings and disagrees in other ones with the study of Osman
et al. (2012) who revealed that serum chemerin was correlated
positively with each of systolic blood pressure, diastolic blood
pressure, waist circumference, fasting serum insulin, HOMA-
IR, total cholesterol, LDL-C and triglycerides in metabolic
syndrome patients, and they revealed no correlation with
either FBS or PPBS. Moreover, a significant positive correlation
was found between serum chemerin levels and each of IL6,
TNF, CRP and carotideIMT and baPWV in both groups
(p < 0.01, respectively). These results agree with the study of
Dong et al. (2011) who proved that serum chemerin in MetS
subjects was positively correlated with CRP who demonstrate
the association of serum chemerin levels with the develop-
ment of CAD in patients with MetS. Previous studies have
suggested that elevated serum chemerin levels are strongly
related to inflammatory markers such as high sensitivity CRP,interleukin-6 and tumor necrosis factor-a (Weigert et al., 2010;
Lehrke et al., 2009). TNF-a treatment of 3T3-L1 adipocytes
increased bioactive chemerin levels, suggesting that inflam-
matory cytokines contribute to the up-regulation of chemerin
in obesity (Parlee et al., 2010). Thus, it is possible that
adipocyte-derived chemerin may be involved in the patho-
genesis of obesity-related inflammatory disorders, including
atherosclerosis. These results are also in consistence with the
study of Yoo et al. (2012) who demonstrated that the circu-
lating chemerin level was positively associated with arterial
stiffness, as represented by the baPWV, and the serum
chemerin level was an independent determining factor for the
baPWV, even after adjusting for other cardiovascular risk
factors but our results disagree with this study regarding IMT
which revealed non significant correlation with chemerin
levels.
McCarthy et al. (2008) explained our findings by the ability
of chemerin for chemotactic recruitment for macrophages
and dendritic cells expressing CMKLR1, as well as its ability to
promote cholesterol uptake and foam cell formation, suggests
a role of chemerin in inflammatory states and possibly
atherosclerosis. In addition, Lehrke et al. (2009) proved that
chemerin is strongly related to markers of inflammation as
tumor necrosis factor-a, interlukin-6 and CRP. Thus, it is
conceivable that chemerin may be up-regulated in states of
inflammation such as obesity, metabolic syndrome and
atherosclerosis to dampen inflammatory processes and to
improve metabolic regulation.
Stepwise multiple regression analysis in metabolic syn-
drome group revealed that chemerin, SBP and WC are risk
factors in determining baPWV values. Chemerin alone in
model 1, chemerin together with SBP in model 2 and chem-
erin, SBP and WC in model 3 account for 46.0% (F ¼ 15.308,
p ¼ .001) and 69.7% (F ¼ 19.586, p ¼ <.001) and 76.9%
(F ¼ 17.713, p ¼ <.001) of the variance in baPWV values
respectively. Our results agree with the results of Yoo et al.
(2012) who proved that age, waist circumference, systolic
blood pressure, and serum fasting glucose and chemerin
levels were definitive risk factors for arterial stiffness. Lehrke
et al. (2009) showed that circulating chemerin had a positive
correlation with atherosclerotic plaque burden assessed by
multislice CT angiography (Mark et al., 2010). Arterial stiffness
is recognized as a result of structural and functional changes
of the vascular tree (O’Rourke and Mancia 1999).
Carotid IMTquantitativelymeasuresthearterialmorphology
consisting of intimal lesions and medial hypertrophy (Simon
et al., 2002). Many studies have shown that PWV is an inde-
pendent risk factor for cardiovascular disease; Cruickshank
et al. (2002) during a 10-year follow-up period, reported that
arterial stiffness independently predicted all-cause and cardio-
vascular mortality in 397 diabetic patients for each 1 m/s in-
crease in PWV (hazard ratio, 1.08; 95% confidence interval,
1.03e1.14); therefore, our results suggest that circulating
chemerin may directly mediate the process of cardiovascular
disease. Hart and Greaves 2010, showed that chemerin rapidly
stimulated the adhesion of macrophages to the extracellular
matrix protein, fibronectin, and to the adhesion molecule,
vascular cell adhesion molecule-1, suggesting that chemerin
might promote the progression of atherosclerosis. Kaur et al.
(2010) demonstrated the novel presence of a G-protein coupled
b e n i - s u e f un i v e r s i t y j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 3 ) 8 6e9 594chemerin receptor (CMKLR1) in human endothelial cells and its
significant up-regulation by pro-inflammatory cytokines (TNF-
a, IL-1b, and IL-6). Thus, the altered expression of chemerin and
its receptors during an inflammatory process may cause dys-
regulated angiogenesis, leading to the development of cardio-
vascular disease. In conclusion, the present study confirmed
that the circulating chemerin level is significantly elevated in
metabolic syndrome and type 2 diabetes mellitus individuals
andhasa closecorrelationwithvariousmetabolic risk factors. It
can be also suggested that chemerin is associatedwithmarkers
of inflammation, and predictors of atherosclerosis in the
metabolic syndrome, and type 2 diabetes and we revealed that
chemerin, systolic blood pressure and waist circumference are
important risk factors determining arterial stiffness in Saudi
Arabians. The influence of chemerin on the predictors of
atherosclerosis and the control of diabetes and metabolic syn-
drome opens a new era in the field of prevention of atheroscle-
rosis and cardiovascular diseases that accompany these
conditions. Further experimental studies are warranted to
clarify the role of chemerin in the atherosclerotic process.r e f e r e n c e s
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